July 2, 2024: MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Independent Data Safety and Monitoring Board (DSMB) recommended that the trial proceeds as planned without modifications. MaaT033 has shown to have an acceptable safety profile and was well tolerated in patients [...] 
